Current Ratio
since 2012
Calculation
AbbVie Inc., current ratio, long-term trends, calculation
| Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
|---|---|---|---|---|---|
| Dec 31, 2024 | 0.66 | = | 25,582) | ÷ | 38,749) |
| Dec 31, 2023 | 0.87 | = | 33,002) | ÷ | 37,841) |
| Dec 31, 2022 | 0.96 | = | 28,463) | ÷ | 29,538) |
| Dec 31, 2021 | 0.79 | = | 27,928) | ÷ | 35,194) |
| Dec 31, 2020 | 0.84 | = | 24,173) | ÷ | 28,661) |
| Dec 31, 2019 | 3.18 | = | 49,519) | ÷ | 15,585) |
| Dec 31, 2018 | 0.98 | = | 16,945) | ÷ | 17,239) |
| Dec 31, 2017 | 1.28 | = | 21,223) | ÷ | 16,641) |
| Dec 31, 2016 | 1.65 | = | 16,187) | ÷ | 9,781) |
| Dec 31, 2015 | 1.50 | = | 16,314) | ÷ | 10,894) |
| Dec 31, 2014 | 1.41 | = | 16,088) | ÷ | 11,400) |
| Dec 31, 2013 | 2.59 | = | 17,848) | ÷ | 6,879) |
| Dec 31, 2012 | 2.27 | = | 15,354) | ÷ | 6,776) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$ in millions
The financial data reveals significant fluctuations in liquidity and working capital management over the analyzed period. Current assets exhibit variability with notable peaks and troughs. After a generally stable level around 16,000 to 21,000 million US dollars between 2012 and 2018, there is a pronounced spike in 2019, reaching nearly 50,000 million US dollars. This surge is followed by a decline in 2020 and gradual recovery through 2023, before falling again in 2024.
Current liabilities show an overall increasing trend, with the exceptions of some fluctuations. They remain relatively moderate from 2012 through 2016 but rise sharply in 2017, maintaining higher levels thereafter. There is a noticeable increase in 2020 and continuing into subsequent years, with liabilities peaking and stabilizing at a high range around 37,000 to 38,000 million US dollars by 2023 and 2024.
The current ratio, a key indicator of short-term liquidity, depicts considerable volatility and a downward trajectory over time. From a strong position above 2.0 in 2012 and 2013, it declines sharply in the following years, falling below 1.0 from 2018 onwards, except for a spike in 2019 to over 3.0. The ratio drops markedly again after 2019, reaching a low of 0.66 in 2024. This signals diminishing liquidity and a potential challenge in covering short-term obligations with current assets towards the latter years.
- Current Assets
- Generally fluctuating, with peaks in 2019 and dips in 2020 and 2024, moving between approximately 16,000 and 50,000 million US dollars.
- Current Liabilities
- Increasing overall, with a significant rise after 2016, stabilizing at higher levels around 37,000 to 38,000 million US dollars in recent years.
- Current Ratio
- Declining trend from above 2.0 to below 1.0, indicating reduced liquidity; notable spike in 2019 followed by a sharp drop to 0.66 in 2024.
The combination of rising current liabilities and fluctuating current assets, resulting in a decreasing current ratio, suggests increased liquidity risk over time. The exceptional spike in current assets and current ratio in 2019 may indicate extraordinary factors impacting liquidity during that year. Overall, the financial position concerning short-term assets and obligations requires careful monitoring, with attention to the ability to meet current liabilities through available assets.
Comparison to Competitors
AbbVie Inc., current ratio, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 0.66 | 1.26 | 1.25 | 1.40 | 1.15 | 1.60 | 1.11 | 1.36 | 1.17 | 4.73 | 1.66 | 2.69 |
| Dec 31, 2023 | 0.87 | 1.65 | 1.43 | 1.68 | 0.94 | 1.43 | 1.16 | 1.25 | 0.91 | 5.69 | 1.75 | 3.99 |
| Dec 31, 2022 | 0.96 | 1.41 | 1.25 | 1.89 | 1.05 | 1.29 | 0.99 | 1.47 | 1.22 | 5.06 | 1.48 | 4.83 |
| Dec 31, 2021 | 0.79 | 1.59 | 1.52 | 1.43 | 1.23 | 1.27 | 1.35 | 1.27 | 1.40 | 3.56 | 1.50 | 4.46 |
| Dec 31, 2020 | 0.84 | 1.81 | 1.58 | 1.86 | 1.40 | 1.40 | 1.21 | 1.02 | 1.35 | 3.63 | 2.13 | 4.33 |
| Dec 31, 2019 | 3.18 | 1.44 | 1.60 | 5.19 | 1.16 | 3.10 | 1.26 | 1.24 | 0.88 | 3.67 | 1.92 | 3.61 |
| Dec 31, 2018 | 0.98 | 2.79 | 1.61 | 1.47 | 1.73 | 3.38 | 1.47 | 1.17 | 1.57 | 4.47 | 1.73 | 3.43 |
| Dec 31, 2017 | 1.28 | 5.49 | 1.55 | 1.43 | 1.32 | 2.74 | 1.41 | 1.33 | 1.35 | 3.82 | 1.34 | 3.28 |
| Dec 31, 2016 | 1.65 | 4.11 | 1.55 | 0.97 | 1.37 | 2.22 | 2.47 | 1.78 | 1.25 | 2.56 | 1.44 | 2.31 |
| Dec 31, 2015 | 1.50 | 4.44 | 1.30 | 1.27 | 1.53 | 2.50 | 2.17 | 1.55 | 1.49 | 3.59 | 1.38 | 2.78 |
| Dec 31, 2014 | 1.41 | 4.95 | 1.73 | 1.75 | 1.09 | 3.07 | 2.36 | 1.77 | 2.67 | 3.31 | 1.22 | 4.20 |
| Dec 31, 2013 | 2.59 | 3.44 | 1.52 | 2.01 | 1.47 | 1.15 | 2.20 | 2.00 | 2.41 | 6.01 | 3.16 | 3.99 |
| Dec 31, 2012 | 2.27 | 3.81 | 1.15 | 1.80 | 1.55 | 1.44 | 1.90 | 1.90 | 2.15 | 7.37 | 2.31 | 3.67 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 0.66 | 1.24 |
| Dec 31, 2023 | 0.87 | 1.27 |
| Dec 31, 2022 | 0.96 | 1.30 |
| Dec 31, 2021 | 0.79 | 1.36 |
| Dec 31, 2020 | 0.84 | 1.37 |
| Dec 31, 2019 | 3.18 | 1.66 |
| Dec 31, 2018 | 0.98 | 1.71 |
| Dec 31, 2017 | 1.28 | 1.74 |
| Dec 31, 2016 | 1.65 | 1.91 |
| Dec 31, 2015 | 1.50 | 1.90 |
| Dec 31, 2014 | 1.41 | 2.19 |
| Dec 31, 2013 | 2.59 | 2.17 |
| Dec 31, 2012 | 2.27 | 2.04 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc., current ratio, long-term trends, comparison to industry (health care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 0.66 | 1.14 |
| Dec 31, 2023 | 0.87 | 1.17 |
| Dec 31, 2022 | 0.96 | 1.19 |
| Dec 31, 2021 | 0.79 | 1.24 |
| Dec 31, 2020 | 0.84 | 1.24 |
| Dec 31, 2019 | 3.18 | 1.40 |
| Dec 31, 2018 | 0.98 | 1.45 |
| Dec 31, 2017 | 1.28 | 1.49 |
| Dec 31, 2016 | 1.65 | 1.67 |
| Dec 31, 2015 | 1.50 | 1.66 |
| Dec 31, 2014 | 1.41 | 1.87 |
| Dec 31, 2013 | 2.59 | 1.93 |
| Dec 31, 2012 | 2.27 | 1.81 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).